

Thu 1 Dec
10:30 - 11:00 | **Welcome - Opening Ceremony**
Channel 1 Plenary

10:30 Opening ceremony
Alexandra Santos (United Kingdom), Ronald van Ree (Netherlands), Isabel Carrapatoso (Portugal), Bernadette Eberlein (Germany), Mohamed Shamji (United Kingdom)

Thu 1 Dec
11:00 - 12:15 | **Mechanisms & Methods**
Channel 1 Plenary

Chair : Anna Nopp (Sweden)

- To describe and discuss new methods in cellular assays for IgE-mediated allergies**
- 2.1 To describe and discuss new methodological approaches with basophils for detection of clinically relevant allergic sensitization
 - 2.3 To describe and discuss a novel functional mast cell assay for IgE-mediated allergies

11:00 CytoBas: Flow cytometric staining of basophils with recombinant allergen tetramers
2.1 Menno van Zelm (Australia)

11:25 A novel functional mast cell assay for the detection of allergies
2.3 Alexander Eggel (Switzerland)

11:50 Significance of tumour-infiltrating basophils and propensity for ex vivo stimulation of patient-derived circulating basophils
OA1 Jitesh Chauhan (United Kingdom)

12:02 BAT improvement: TLR-4 signaling primes CD63 expression in amoxicillin IgE-mediated hypersensitivity reactions
OA2 Jose Antonio Céspedes (Spain)

Thu 1 Dec
12:25 - 13:50

BAT/MAT in immediate drug hypersensitivity

Channel 1 Plenary

Chair : Cristobalina Mayorga (Spain)

To describe and discuss IgE-independent mechanisms in immediate drug hypersensitivity and to describe drug allergens that recently have become more relevant in the Corona pandemic

3.1 To understand different mast cell receptors in immediate drug hypersensitivity

3.3 To understand the relevance of BAT for allergies to COVID-19 vaccines

12:25 Mast cell receptors beyond IgE and its relevance in immediate drug hypersensitivity

3.1 Vito Sabato (Belgium)

12:50 Basophil activation tests and allergy to COVID-19 vaccines

3.3 Bernadette Eberlein (Germany)

13:15 Usefulness of Basophil Activation Test to evaluate immediate hypersensitivity reactions to chemotherapeutic agents

OA3 Ruben Fernandez-Santamaria (Spain)

13:27 Evaluation of BAT test results against PEG-2000

OA4 Vasiliki Giogli (Greece)

13:39 Basophil Activation Tests with cryopreserved mRNA-based COVID-19 vaccines

OA5 Alessandra Noto (Switzerland)

Thu 1 Dec
15:30 - 16:35

BAT in food allergy

Channel 1 Plenary

Chair : Alexandra Santos (United Kingdom)

To describe and discuss new insights of BAT in food allergy

4.1 To describe and discuss new aspects of BAT in peanut and tree nut allergy

4.3 To describe and discuss new aspects of BAT in allergy to LTP

15:30 Basophil activation test in peanut and tree nut allergy

4.1 Thomas Eiwegger (Austria)

15:55 BAT as a diagnostic tool in allergy to lipid transfer proteins (LTP)

4.3 Cristobalina Mayorga (Spain)

16:20 Basophil activation test (BAT) for the diagnosis of wheat-dependent exercise-induced anaphylaxis (WDEIA)

OA6 Viktoria Schmalhofer (Germany)

Thu 1 Dec
17:00 - 18:15

BAT in immunotherapy

Channel 1 Plenary

Chair : Mohamed Shamji (United Kingdom)

To understand the application of BAT as biomarker during immunotherapy

5.1 To understand and discuss the application of BAT during bee venom immunotherapy

5.3 To understand and discuss the application of BAT during grass pollen immunotherapy

17:00
5.1 **Biomarkers of adverse events during bee venom immunotherapy**
Peter Korosec (Slovenia)

17:25
5.3 **Basophil sensitivity during immunotherapy in grass pollen-allergic patients**
Johannes Schmid (Denmark)

17:50
OA7 **Basophil activation test results change in birch pollen sensitized patients during first season of immunotherapy**
Andrey Kamaev (Russia)

18:02
OA8 **Basophil activation test (BAT) in the assessment of adverse transfusion reactions (ATR)**
Ewa Bartko (Denmark)

 Friday 2 December

FAAM-EURO BAT

Fri 2 Dec
09:00 - 10:30

Risk factors & Prevention of Food Allergy

Channel 1 Plenary

Chair : George du Toit (United Kingdom)

1.1 To explain the effects of diet and microbiome on the immune system and rationale for their use in food allergy prevention

1.3 To describe the recent evidence and ongoing studies on the effect of interventions on the skin barrier in the development of food allergy

1.5 To discuss the practical aspects of introducing allergenic foods in the infants' diet and their implications for public health

09:00
1.1 **Immunonutrition and microbiome for prevention**
Liam O'Mahony (Ireland)

09:25
1.3 **Targeting the skin barrier to prevent food allergy**
Helen Brough (United Kingdom)

09:50
1.5 **Implementing early introduction of allergenic foods**
Graham Roberts (United Kingdom)

10:15
OA9 **Biomarkers, including the mast cell activation test, to predict peanut food allergic outcomes across time**
Ru-Xin Foong (United Kingdom)

Fri 2 Dec
10:45 - 12:15

Best Practice in Food Allergy Diagnosis

Channel 1 Plenary

Chair : Isabel Skypala (United Kingdom)

- 2.1 To enumerate the key messages about food allergy diagnosis reported in the MAUG 2.0
- 2.3 To describe the main findings of the systematic review of the literature that forms the basis for the new EAACI Food Allergy Guidelines
- 2.5 To discuss novel approaches for diagnostic tests for food allergy that are making the transition to clinical practice and their added value to existing tests

10:45 **Highlights of the molecular allergology users' guide**

2.1 Karin Hoffmann-Sommergruber (Austria)

11:10 **Systematic review and meta-analyses on the accuracy of diagnostic tests for IgE-mediated food allergy**

2.3 Carmen Riggioni-Viquez (Singapore)

11:35 **Emerging diagnostic tests for food allergy**

2.5 Alexandra Santos (United Kingdom)

12:00 **Diagnostic utility of various allergy tests to predict baked egg allergic reactions in double-blind placebo-controlled food challenges in children**

OA10 Andreina Marques-Mejias (United Kingdom)

Fri 2 Dec
14:00 - 15:30

Allergens and Immune Mechanisms of Food Allergy

Channel 1 Plenary

Chair : Eva Untersmayr (Austria)

- 3.1 To describe the immune mechanisms underlying FPIES and other non-IgE mediated food allergy clinical entities
- 3.3 To enunciate measures of allergenicity of food proteins and their use in the evaluation of probability of inducing clinical reactions in allergic individuals
- 3.5 To explain the changes in the allergic immune response during dessensitisation and natural acquisition of tolerance

14:00 **Mechanisms of non IgE mediated food allergy**

3.1 Cecilia Berin (United States of America)

14:25 **Allergenicity and risk assessment**

3.3 Ronald van Ree (Netherlands)

14:50 **Immune responses in desensitization and tolerance**

3.5 Michael Kulis (United States of America)

15:15 **Type 2 innate lymphoid cells regulate adaptative Th2 cell response in food-allergic patients**

OA11 Francisca Palomares (Spain)

Fri 2 Dec
15:45 - 17:00

What's new in Anaphylaxis

Channel 1 Plenary

Chair : George Konstantinou (Greece)

4.1 To describe the differences in clinical presentation and management of anaphylaxis induced by different agents using examples from the European anaphylaxis registry

4.3 To explain the physiologic changes during an episode of anaphylaxis based on evidence from food challenges

4.5 To discuss the differences between adrenaline auto-injectors, the evidence supporting its prescription and availability around the world

15:45 **Adrenaline auto-injectors**

4.5 Luciana Tanno (France)

16:10 **Anaphylaxis to drugs, insects and foods: any differences?**

4.1 Margitta Worm (Germany)

16:35 **Physiopathology of anaphylaxis**

4.3 Paul Turner (United Kingdom)

Saturday 3 December

FAAM-EURO BAT

Sat 3 Dec
09:00 - 10:40

Allergen-Specific Immunotherapy for Food Allergy

Channel 1 Plenary

Chair : Alberto Alvarez-Perea (Spain)

1.1 To explain the mechanism, efficacy and safety of nanoparticles as a vehicle of food allergen immunotherapy

1.3 To articulate the mechanisms and possible indications of adjuvants of food allergen immunotherapy

1.5 To outline the practicalities and challenges of starting and maintaining a food allergen immunotherapy service

09:00 **Nanoparticles approaches in food allergy immunotherapy**

1.1 Mohamed Shamji (United Kingdom)

09:25 **Adjuvants in immunotherapy**

1.3 Kirsten Perrett (Australia)

09:50 **Implementing immunotherapy in clinics**

1.5 Pablo Rodríguez del Río (Spain)

10:15 **Stratifying the Linear Epitope Repertoires to Peanut Allergens Revealed Distinct Phenotypes of IgE and IgG4**

OA12 Nicki Shwe Yee (Australia)

10:27 **Sustained unresponsiveness to tree nuts after low dose oral immunotherapy in children aged 9-24 months**

OA13 Lieke Barten (Netherlands)

Sat 3 Dec
10:50 - 12:20

How Allergen Thresholds can inform Clinical Management of the food Allergic Patient

Channel 1 Plenary

Chair : Alexandra Santos (United Kingdom)

- 2.1 To elaborate on the use of allergen threshold to inform clinical decision making and recommendations to patients
- 2.2 To explain the implications of allergen threshold for the practical daily management of food allergies
- 2.3 To identify the issues that allergen thresholds can help address in the food industry
- 2.4 To report the limitations of methods used for detection of allergen in foods and utility of allergen thresholds
- 2.5 To recognise the methods used to calculate allergen thresholds at the population and the individual level

10:50
2.1 **The clinical' perspective**
Montserrat Fernandez-Rivas (Spain)

11:00
2.2 **The patient' perspective**
Sabine Schnadt (Germany)

11:10
2.3 **Food industry perspective**
Rene Crevel (United Kingdom)

11:20
2.4 **The science perspective**
Clare Mills (United Kingdom)

11:30
2.5 **The data scientist perspective**
Benjamin C. Remington (Netherlands)

11:40
2.6 **Panel discussion and Q&A**
Jennifer Gerdtts (Canada), Berber Vlieg (Netherlands), Rebecca Knibb (United Kingdom)

Sat 3 Dec

12:30 - 13:45

Poster Discussion Session - EUROBAT

Channel 1 ePoster Discussion

Chair : Bernadette Eberlein (Germany)

12:30
PP1 **Usefulness of the basophil activation test in the diagnosis of anaphylaxis after the second dose of the anti-COVID-19 vaccine – case report**

Maria Czarnobilska (Poland)

12:38
PP2 **Basophil activation test: feedbacks and lessons from routine practices in French clinical laboratories**

Julien Goret (France)

12:46
PP3 **Validation studies for Basophil Activation Test according to IVDR with new non-responder rate observations**

Martina Berchtold (Switzerland)

12:54
PP4 **How accuracy of the basophil activation test (BAT) is influenced by activation level and basophil count**

Christina Bauer (Switzerland)

13:02
PP5 **Basophil activation test with gadolinium contrast agent**

Alberto Palacios Cañas (Spain)

13:10
PP6 **Basophil activation test: useful diagnostic and therapeutic tool in Rivaroxaban allergy**

Leticia De las Vecillas (Spain)

13:18
PP7 **Usefulness of the basophil activation test as a diagnostic tool in the study of immediate hypersensitivity reactions to chemotherapeutic agents and monoclonal antibodies**

Sònia Gelis (Spain)

13:26
PP8 **Avoiding Dietary Salicylate Ameliorates the Severity of Chronic Spontaneous Urticaria**

Sercan Guloglu (Turkey)

13:34
PP9 **Repeatability and Reproducibility of the Basophil Activation Test in the Transition Process to IVDR**

Sergio Sánchez Fernández (Spain)

Sat 3 Dec

12:30 - 13:45

Poster Discussion Session - Immunotherapy

Poster Discussion Room 2 ePoster Discussion

Chair : Karin Hoffmann-Sommergruber (Austria)

12:30
PP10 **Long-term Safety Profile and Immunological Outcomes of Daily Oral Immunotherapy With Peanut (*Arachis hypogaea*) Allergen Powder-dnfp for Peanut Allergy Up to ~5 Years: A Pooled Analysis of 6 Trials**
Caroline Nilsson (Sweden)

12:38
PP11 **Efficacy and Safety of Oral Immunotherapy for Peanut Allergy in Children Aged 1 to <4 Years: Results From the POSEIDON Trial**
George du Toit (United Kingdom)

12:46
PP12 **Baseline Immunoglobulin E Levels to Peanut and Peanut Allergen Components in Children With Peanut Allergy Responding Versus Not Responding to Peanut Oral Immunotherapy: Findings From the PALISADE Trial**
Caroline Nilsson (Sweden)

12:54
PP13 **A qualitative study exploring the impact of licensed oral immunotherapy for peanut allergy on caregivers' health-related quality of life**
Ginny Shand (United Kingdom)

13:02
PP14 **A qualitative study exploring the impact of licensed oral immunotherapy for peanut allergy on patient health-related quality of life**
Ginny Shand (United Kingdom)

13:10
PP15 **Plant food allergy: looking for clinical and allergenic patterns**
Daniela Brandão Abreu (Portugal)

13:18
PP16 **The Prospective Advances of Platelet-Activating Factor Acetylhydrolase as Anaphylaxis Prognosis Biomarker Among Allergy Patients: A Systematic Review**
Boby Pratama Putra (Indonesia)

13:26
PP17 **Alpha-livetin sensitization and bird-egg syndrome**
Sónia Garcia (Portugal)

Sat 3 Dec

12:30 - 13:45

Poster Discussion Session - Allergy Diagnosis

Poster Discussion Room 3 ePoster Discussion

Chair : Montserrat Fernandez-Rivas (Spain)

12:30
PP18 **Salivary histamine as biomarker for oral food challenge outcome in children**
Wouter De Weger (Netherlands)

12:38
PP19 **Fish Allergy: Clinical Characterization and Search for Factors Associated with Severity**
Helena Pires Pereira (Portugal)

12:46
PP20 **Skin prick test and specific IgE to cow's milk and egg for clinical decision making regarding oral food challenge referral**
Evi van Goor (Netherlands)

12:54
PP21 **Angioedema Beyond Food Allergy - Case Reports in Twins**
Helena Pires Pereira (Portugal)

13:02
PP22 **Food-dependent exercise-induced anaphylaxis to orange, with possible underlying thaumatin-like protein allergy**
Katherine Townsend (United Kingdom)

13:10
PP23 **Beluga caviar. An uncommon seafood allergy**
R Paulauskas-vasaitis (Spain)

13:18
PP24 **Delayed onset cashew nut allergy in a type 1 diabetic with gastroparesis**
Anthony Dorr (United Kingdom)

13:26
PP25 **Evaluation of sensitization to nsLTP proteins using allergen extracts and molecular components: a pilot study**
Sandra Sakalauskaite (Lithuania)

13:34
PP26 **Pork-cat syndrome: the role of precision allergology**
João Cardoso Lopes (Portugal)

Sat 3 Dec

12:30 - 13:45

Poster Discussion Session - Anaphylaxis

Poster Discussion Room 4 ePoster Discussion

Chair : Alexandra Santos (United Kingdom)

12:30
PP27 **LTP syndrome – clinical characterization and factors associated with severity**
Inês Farinha (Portugal)

12:38
PP28 **Shelling the Peanut – characterizing Peanut Allergy with the new Food Allergy Severity Score**
Pedro Alves (Portugal)

12:46
PP29 **Initial and repetitive reactions in the European Anaphylaxis Registry - a comparative analysis**
Veronika Höfer (Germany)

12:54
PP30 **The importance of shape in the design of adrenaline auto-injectors**
Alice Coimbra (Portugal)

13:02
PP31 **Anaphylaxis in the emergency department of a tertiary hospital: from the initial event to the final diagnosis**
Ana Luísa Pinhal (Portugal)

13:10
PP33 **Anaphylaxis in the operating room: a pediatric case series**
Diogo Mota (Portugal)

13:18
PP34 **Anaphylaxis to Milk After Elimination Diet for Eosinophilic Esophagitis in an adult**
Cristiana Ferreira (Portugal)

13:26
PP35 **Stratifying Characteristics and Severity of Sesame allergy among Saudi Arabian population: Single referral center study**
wyam Alshaikh (Saudi Arabia)

Sat 3 Dec

12:30 - 13:45

Poster Discussion Session - Food Allergy

Poster Discussion Room 5 ePoster Discussion

Chair : Isabel Carrapatoso (Portugal)

12:30
PP36 **Different Major Allergens are Identified in Chinese and Thai Patients with Shrimp Allergy**
Ting Fan Leung (Hong Kong)

12:38
PP37 **Sampling plans for food allergen quantification. Scenario milk contamination in rice flour**
Ana I. Sancho (Denmark)

12:46
PP38 **Food Allergy-specific Questionnaire Series Developed by EuroPrevall are Valid and Useful for Assessing Chinese Patients and Children's Caregivers**
Christy Wing Man Leung (Hong Kong)

12:54
PP39 **Quality of life among children with food allergy and their caregivers attending a national allergy clinic in Sri Lanka**
Deneshan Peranantharajah (Sri Lanka)

13:02
PP40 **Allergenicity assessment of innovative food proteins: state of play and way forward**
Antonio Fernandez Dumont (Italy)

13:10
PP41 **Food allergy to sheep's milk proteins in an adult patient**
Ana Raquel Pinto (Portugal)

13:18
PP42 **The role of house dust mites in milk and egg allergy**
Mariana Bragança (Portugal)

13:26
PP43 **Recurring peanut allergy after tolerance acquisition**
Liliana Pereira Dias (Portugal)

Sat 3 Dec

12:30 - 13:45

Poster Discussion Session - Paediatrics

Poster Discussion Room 7 ePoster Discussion

Chair : Pablo Rodríguez del Río (Spain)

12:30
PP53 **Der p 10 sensitization and shrimp allergy in House Dust Mite allergic children**
Jóni Costa Carvalho (Portugal)

12:38
PP54 **Predicting of anaphylaxis in oral food challenges with cow's milk**
Otso Nieminen (Finland)

12:46
PP56 **Using egg-ladder as a smooth way to achieve tolerance to cooked egg in IgE mediated egg allergy**
Laura Argiz (Spain)

12:54
PP57 **Pru du γ -conglutin as an allergen causing a severe reaction with almonds in a child**
Cristina Rivas Juesas (Spain)

13:02
PP58 **A review of shifting practice in Infant Peanut Oral Food Challenges at a single centre**
Aisling Stafford (Ireland)

13:10
PP59 **Food anaphylaxis in toddlers: diagnostic measurement and identification of fundamental causes**
Oksana Matsyura (Ukraine)

Sat 3 Dec

12:30 - 13:45

Poster Discussion Session - Miscellaneous

Poster Discussion Room 6 ePoster Discussion

Chair : Ronald van Ree (Netherlands)

12:30 **Human IgE Monoclonal Antibodies Targeting Alpha-gal and the Major Peanut Allergens**
PP45 BRYAN SMITH (United States of America)

12:38 **Association between physicochemical and immunological properties of cow's milk-based hydrolysates**
PP46 Katrine Bøgh (Denmark)

12:46 **Toll-like receptor ligand-peptide conjugates in the immunomodulatory response to food allergy**
PP47 Francisca Palomares (Spain)

12:54 **Baseline Demographics and Disease Characteristics of Patients With Eosinophilic Esophagitis Enrolled in Part B of the 3-Part, Randomized, Placebo-Controlled, Phase 3 TREET Study**
PP48 Evan Dellon (United States of America)

13:02 **Eosinophilic esophagitis: a series of cases**
PP50 Francisca Cunha (Portugal)

13:10 **Latex Fruit Syndrome: A Series of Cases**
PP51 Helena Pires Pereira (Portugal)

Sat 3 Dec

14:00 - 15:30

Biologics and new therapeutic approaches for food allergy

Channel 1 Plenary

Chair : Thomas Eiwegger (Austria)

3.1 To describe current evidence about the efficacy and safety of anti-IgE antibodies in the treatment of food allergy

3.3 To explain the mechanism and clinical evidence to support the use of small molecules in the treatment of food allergy

3.5 To outline the generation of allergen-specific monoclonal antibodies from human samples and its potential application in therapy of food allergy

14:00

3.1

Is there a role for anti-IgE biologics as monotherapy for food allergy?

Sharon Chinthrajah (United States of America)

14:25

3.3

Small molecules for inhibiting IgE synthesis and function

Alexander Eggel (Switzerland)

14:50

3.5

Allergen-specific monoclonal antibody cocktails

Derek Croote (United States of America)

15:15

OA14

Influence of antigen density and TLR ligands on efficacy of a VLP-based vaccine against Peanut Allergy: mechanistic insights

Matthew D. Heath (United Kingdom)

Sat 3 Dec

15:45 - 16:00

Closing Addresses

Channel 1 Plenary

15:45

4.1

Closure

Alexandra Santos (United Kingdom), Ronald van Ree (Netherlands), Isabel Carrapatoso (Portugal), Bernadette Eberlein (Germany)